Possible active transport mechanism in pharmacokinetics of flunixin-meglumin in rabbits

被引:17
作者
Miyazaki, Y
Horii, Y
Ikenaga, N
Shimoda, M
Kokue, E [1 ]
机构
[1] Tokyo Univ Agr & Technol, Fac Agr, Lab Vet Pharmacol, Tokyo 1838509, Japan
[2] Daiichi Pharmaceut Co Ltd, Div Anim Sci, Res Labs, Osaka 5630011, Japan
[3] Gifu Univ, United Grad Sch Vet Sci, Gifu 5011193, Japan
关键词
active transport; flunixin-meglumin; OATP-2; pharmacokinetics; rabbit;
D O I
10.1292/jvms.63.885
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The plasma and urine kinetics of flunixin-meglumin (FNX, 2 mg/kg, i.v.) in rabbits were examined. Unusual pharmacokinetic profiles were obtained, including high binding percentage with plasma protein (> 99%), a short elimination half-life (< 4 hr) and a relatively large Vd-area (0.5 L/kg). These profiles indicate that some active transport mechanisms are involved in FNX disposition. The recovery of FNX from urine was approximately 9 % of the dose within 24 hr following the injection. The estimated renal clearance of the unbound drug nearly corresponded to the renal blood flow rates, indicating that active tubular secretion in the renal re-absorptive tract may be involved in the disposition. The effect of a concomitant administration of pravastatin (PV) on FNX disposition was also examined. PV is a representative substrate of a transporter in human liver cells (OATP-2). After the PV administrations, the Vd-area of FNX and total body clearance markedly decreased, indicating that FNX is actively taken up and metabolized in liver cells by an OATP-2 like transporter. In conclusion, there are at least 2 active transport pathways for FNX pharmacokinetics in rabbits, one is renal tubular secretion and the other is in the sinusoidal section of the liver.
引用
收藏
页码:885 / 888
页数:4
相关论文
共 18 条
[1]  
ANDERSON KL, 1990, AM J VET RES, V51, P1464
[2]  
Backer P. de, 1980, Journal of Veterinary Pharmacology and Therapeutics, V3, P29, DOI 10.1111/j.1365-2885.1980.tb00476.x
[3]   Expression of the liver Na+-independent organic anion transporting polypeptide (oatp-1) in rats with bile duct ligation [J].
Dumont, M ;
Jacquemin, E ;
DHont, C ;
Descout, C ;
Cresteil, D ;
Haouzi, D ;
Desrochers, M ;
Stieger, B ;
Hadchouel, M ;
Erlinger, S .
JOURNAL OF HEPATOLOGY, 1997, 27 (06) :1051-1056
[4]   PHARMACOKINETICS OF FLUNIXIN MEGLUMINE IN THE COW [J].
HARDEE, GE ;
SMITH, JA ;
HARRIS, SJ .
RESEARCH IN VETERINARY SCIENCE, 1985, 39 (01) :110-112
[5]  
HARDIE EM, 1985, AM J VET RES, V46, P235
[6]   EFFECTS OF SIMVASTATIN AND PRAVASTATIN ON 6-BETA-HYDROXYCORTISOL EXCRETION, A POTENTIAL MARKER OF CYTOCHROME-P-450-3A [J].
HORSMANS, Y ;
DESAGER, JP ;
VANDENBERGE, V ;
ABRASSART, M ;
HARVENGT, C .
PHARMACOLOGICAL RESEARCH, 1993, 28 (03) :243-248
[7]   A novel human hepatic organic anion transporting polypeptide (OATP2) - Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters [J].
Hsiang, BN ;
Zhu, YJ ;
Wang, ZQ ;
Wu, YL ;
Sasseville, V ;
Yang, WP ;
Kirchgessner, TG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (52) :37161-37168
[8]   EVALUATION OF THE UPTAKE OF PRAVASTATIN BY PERFUSED-RAT-LIVER AND PRIMARY CULTURED RAT HEPATOCYTES [J].
ISHIGAMI, M ;
TOKUI, T ;
KOMAI, T ;
TSUKAHARA, K ;
YAMAZAKI, M ;
SUGIYAMA, Y .
PHARMACEUTICAL RESEARCH, 1995, 12 (11) :1741-1745
[9]   Reduced folate derivatives are endogenous substrates for cMOAT in rats [J].
Kusuhara, H ;
Han, YH ;
Shimoda, M ;
Kokue, E ;
Suzuki, H ;
Sugiyama, Y .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1998, 275 (04) :G789-G796
[10]  
LEES P, 1991, BRIT VET J, V147, P298, DOI 10.1016/0007-1935(91)90002-5